Never Fuck with Mother Nature: GLP-1 receptors, Blindness, and the Price of Biological Intervention

Few things are more terrifying than blindness in someone who has always been able to see.

Not blurred vision. Not needing stronger glasses. Blindness. The sudden realization that an eye that worked yesterday may never work the same way again. That possibility has entered the increasingly complicated conversation surrounding GLP-1 receptor agonists, one of the most consequential classes of medications introduced into modern metabolic medicine.

And before anyone runs to opposite corners of the internet, this deserves some perspective.

GLP-1 receptor agonists have changed medicine.

For patients with type 2 diabetes, obesity, cardiovascular disease, and other metabolic conditions, these drugs can provide substantial benefit.

They improve glycemic control. They can produce significant weight loss. Some have demonstrated cardiovascular and renal benefits. Those facts matter. So does another one. Medicine rarely gives us benefit without asking us to consider risk.

The Signal We Cannot Ignore

A 2026 population-based study by Tesfaye and colleagues examined the relationship between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy, better known as NAION. NAION is an ischemic injury of the optic nerve. In simpler terms, blood flow to part of the optic nerve becomes inadequate. The nerve is injured.

Vision can be lost. And that loss may be permanent.

The investigators examined nearly half a million matched pairs of patients with type 2 diabetes who were beginning either a GLP-1 receptor agonist or an SGLT2 inhibitor.

The result deserves attention. Patients initiating GLP-1 receptor agonists had an approximately 85% higher relative risk of presumed NAION compared with patients initiating SGLT2 inhibitors.

That number sounds enormous. But medicine lives in the denominator. The actual rates were approximately 0.61 events per 1,000 person-years among GLP-1RA users compared with 0.33 among SGLT2 inhibitor users. The absolute increase was approximately 0.29 cases per 1,000 person-years. Rare. But not zero.

And when the outcome being discussed is irreversible visual loss, rare still matters.

The study also deserves an important qualifier: it was observational. Claims data were used to identify presumed cases of NAION, follow-up was relatively short, and residual confounding cannot be eliminated completely. Association is not the same thing as mechanism. And association alone does not tell us precisely why something happened.

That is where this story becomes much more interesting.

Semaglutide Has Moved Beyond a Whisper

The concern is no longer based on a single isolated report.

In 2025, the European Medicines Agency reviewed clinical trials, epidemiologic studies, post-marketing surveillance, and other available evidence involving semaglutide.

Its Pharmacovigilance Risk Assessment Committee concluded that NAION should be classified as a very rare adverse effect of semaglutide.

Very rare generally means fewer than one case per 10,000 treated individuals.

The EMA estimated that epidemiological evidence suggested roughly one additional NAION case per 10,000 person-years of semaglutide treatment.

That puts the risk into perspective. It does not make it meaningless.

Regulators went even further, concluding that available evidence supported a causal relationship between semaglutide specifically and NAION.

That distinction matters.

Semaglutide is a GLP-1 receptor agonist. But semaglutide is not synonymous with every GLP-1 receptor agonist. In the Tesfaye study, semaglutide demonstrated an elevated signal. Dulaglutide did not demonstrate the same meaningful increase.

So we should resist doing what humans repeatedly do with medical information: Turning nuance into absolutes. GLP-1s are not suddenly poison.

We should not dismiss every emerging safety signal just because millions of people take them without difficulty.

Both reactions require less thinking than the evidence deserves.

Never Fuck with Mother Nature

I have a saying.

Actually, I have several.

They probably shouldn't appear in discharge instructions.

But one has followed me through medicine for years:

Never fuck with Mother Nature. Anyone who has underestimated an ocean, thunderstorm, hurricane, winter road, or rising river understands the principle. Nature does not care about your confidence. Human physiology deserves the same respect.

Outside of interventions intended to correct a disease process, I become increasingly cautious whenever we deliberately manipulate biology simply because we believe we have figured out how.

That does not mean we should not intervene. Medicine is intervention.

• Insulin manipulates physiology.

• Antihypertensives manipulate physiology.

• Chemotherapy manipulates cellular replication.

• Pacemakers manipulate cardiac conduction.

• Anesthesia temporarily dismantles consciousness itself.

We interfere with biology every day because sometimes biology is killing the patient.

The question is not whether we should interfere.

The question is whether we remain humble enough to recognize that every biological lever may be attached to something we haven't fully mapped yet.

Pull one. Something else may move.

Biology Is a Network, not a Collection of Buttons

This is one of modern medicine's recurring mistakes.

We talk about physiological systems as if they operate independently.

• Lower glucose.

• Suppress appetite.

• Lower blood pressure.

• Slow gastric emptying.

• Reduce body weight.

Done. Except the body doesn't work that way. Glucose regulation intersects with vascular function. Blood pressure influences tissue perfusion. Hydration influences circulating volume. Weight loss changes metabolic demand. Sleep apnea influences oxygenation. Diabetes damages microvasculature.

GLP-1s & Blindness

And the optic nerve sits downstream from all of it, dependent on extraordinarily small vessels delivering enough blood to sustain one of the most metabolically demanding tissues in the human body.

The authors of the 2026 study raise several possible explanations for the NAION signal, including blood-pressure-related hemodynamic changes, rapid weight loss, vascular autoregulation, fluid balance, diabetic microvascular disease, and individual anatomical susceptibility.

Those are hypotheses. Not verdicts. But they illustrate the larger point. Human physiology does not operate in silos. There is no isolated metabolic switch.

Relative Risk Is Not Absolute Risk

This is another place where medical communication frequently fails.

An 85% increase in relative risk sounds terrifying. A difference of 0.29 cases per 1,000 person-years sounds almost trivial. Both describe the same finding. Neither should be presented alone. Relative risk tells us whether a signal may exist. Absolute risk tells us how frequently the event actually occurs.

Patients deserve both numbers.

A medication can carry a very small absolute risk of a catastrophic complication while still providing enormous benefit to hundreds of thousands of people. Those concepts are not contradictory. That is medicine. Benefit and risk sitting at the same table.

The Population Taking These Drugs Matters

Another problem is buried in this research. People receiving GLP-1 receptor agonists are not biologically neutral research subjects.

• Many have diabetes.

• Obesity.

• Hypertension.

• Sleep apnea.

• Dyslipidemia.

• Cardiovascular disease.

• Microvascular disease.

And several of those conditions independently increase vascular risk. That makes determining causation extraordinarily difficult. Did the medication cause the event?

Did it contribute?

• Did rapid metabolic change expose an existing vulnerability?

• Was the patient already predisposed to optic nerve ischemia?

• Was the medication simply one variable among twenty?

• Or is there a pharmacological effect we have not fully identified?

Sometimes medicine does not know yet. Saying that is not weakness. It is scientific honesty.

The Millions-Person Experiment

This is the part of pharmaceutical medicine that deserves more public understanding.

Clinical trials can involve thousands or tens of thousands of people. Then a successful medication reaches the market. Suddenly millions take it. Rare events that would be almost impossible to identify during a clinical trial begin appearing. One event in ten thousand sounds extraordinarily uncommon.

Give a medication to ten million people and mathematics changes the conversation.

Post-marketing surveillance is therefore not an admission that the original science failed.

It is part of the science. Clinical trials tell us a tremendous amount. Populations tell us the rest. And populations take time.

Medicine Should Be Powerful Enough to Intervene—and Humble Enough to Watch

I am not anti-GLP-1. That would ignore the evidence. These medications have provided meaningful improvements for people struggling with diseases that themselves produce blindness, renal failure, myocardial infarction, stroke, neuropathy, disability, and premature death. Diabetes itself can take someone's sight. So can uncontrolled hypertension. So can vascular disease.

Doing nothing has consequences too. That is why the emerging NAION evidence should not trigger panic. It should trigger vigilance. There is a difference.

We should continue asking whether the signal is specific to semaglutide or extends more broadly across the class.

• Whether dose matters.

• Whether the speed of weight loss matters.

• Whether rapid reductions in glucose or blood pressure matter.

• Whether certain optic nerve anatomies create greater susceptibility.

• Whether sleep apnea modifies the risk.

• Whether the complication can be predicted.

• Whether it can be prevented.

And perhaps most importantly: Who is vulnerable?

Those are the questions medicine should be asking now.

Respect the Biology

The history of medicine is filled with treatments that looked different after millions of people used them. That does not make medicine reckless. It makes biology complicated.

We should resist the temptation to turn every new medication into either a miracle or a menace. Nothing biological is that simple.

GLP-1 receptor agonists may ultimately become one of the most important therapeutic advances of this generation. They may also teach us things about metabolism, vascular physiology, rapid weight loss, and optic nerve perfusion that we did not understand when the first prescriptions were written.

Both things can be true.

Because when we interfere with human physiology—even intelligently, carefully, and for good reason—we enter a system shaped by millions of years of evolution. And evolution leaves very few unused connections.

That is why I keep returning to the same crude little rule.

Never fuck with Mother Nature.

Not because we should leave disease untreated. Not because medicine should fear intervention. But because every time we move human physiology away from its existing state, we should have enough respect for biology to keep watching what moves with it.

The benefit may be enormous. The risk may be microscopic. But medicine owes patients both sides of the equation. Especially when what may be lost is something they cannot get back.

Reference

Tesfaye, H., Paik, J. M., Wexler, D. J., Hathaway, J. T., Yu, E. W., Freedman, A., Rizzo, J. F., III, & Patorno, E. (2026). GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study. Diabetes, Obesity and Metabolism, 28(2), 1517–1528. https://doi.org/10.1111/dom.70200